Related Experiment Videos
Acetylcysteine (Fabrol) in chronic bronchitis--a study in general practice.
The Journal of International Medical Research
|January 1, 1983
Summary
Acetylcysteine (Fabrol) treatment for chronic bronchitis improved sputum viscosity and cough severity. Patients experienced easier expectoration and reduced dyspnea, with good tolerability in 81% of cases.
Area of Science:
- Respiratory Medicine
- Pharmacology
Background:
- Chronic bronchitis is characterized by persistent cough and sputum production.
- Sputum viscosity and difficulty in expectoration are common debilitating symptoms.
Purpose of the Study:
- To evaluate the efficacy of oral acetylcysteine (Fabrol) in managing chronic bronchitis symptoms.
- To assess the impact of acetylcysteine on sputum characteristics and patient-reported outcomes.
Main Methods:
- A general practice study involving patients with chronic bronchitis.
- Oral administration of acetylcysteine (Fabrol) for a duration of 2 months.
Main Results:
- Acetylcysteine effectively altered sputum viscosity and character, easing expectoration and reducing cough severity.
- Significant improvements were observed in physical signs like rhonchi and crepitations, and symptoms such as dyspnea at rest.
- 81% of patients reported good tolerability with no adverse side-effects.
Conclusions:
- Oral acetylcysteine (Fabrol) is an effective treatment for chronic bronchitis.
- The medication improves key respiratory symptoms and physical signs with good patient tolerance.